← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Protagonist Therapeutics, Inc.
Newark, CA
$3,239,151
Total funding
4
Grants
Funding over time
peak $1.1M · FY2015–19$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,239,151 · 4
By mechanism
R44$2,796,377 · 2
R43$442,774 · 2
Investigators at Protagonist Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Developing the required biomarkers that define IL-23R target engagement and effect on downstream signaling for late stage drug development and early clinical proof-of-concept$970,534
R44 · FY2017 · DK
Developing the required biomarkers that define ferroportin target engagement and impact on downstream signaling for clinical translation$758,874
R44 · FY2018 · HL
Developing the required biomarkers that define ferroportin target engagement and impact on downstream signaling for clinical translation$693,188
R44 · FY2019 · HL
Developing the required biomarkers that define IL-23R target engagement and effect on downstream signaling for late stage drug development and early clinical proof-of-concept$373,781
R44 · FY2018 · DK
Orally delivered antagonists of Interleukin-23 receptor for treatment of inflammatory bowel disease$223,946
R43 · FY2015 · DK
Hepcidin Mimetics for the Treatment of Iron Overload Diseases$218,828
R43 · FY2016 · HL